FAQ: Alzamend Neuro Inc.'s Innovative Approach to Mental Health and Neurological Disorders

What conditions is Alzamend Neuro Inc. targeting with its therapies?

Alzamend Neuro Inc. is targeting Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD) with its innovative therapies.

What is AL001 and how does it differ from current treatments?

AL001 is a patented ionic cocrystal formulation of lithium designed to penetrate the brain more effectively while reducing systemic side effects, offering a significant improvement over traditional lithium carbonate treatments.

Are there any ongoing clinical trials for Alzamend’s therapies?

Yes, Phase II trials for AL001 are underway with support from Massachusetts General Hospital and AI partner QMENTA.

What makes ALZN002 unique in the treatment of Alzheimer’s disease?

ALZN002 offers a novel, adjuvant-free immunotherapy approach for Alzheimer’s disease, aiming to provide a safer and more effective treatment option.

Where can I find the latest news and updates about Alzamend Neuro Inc.?

The latest news and updates relating to ALZN are available in the company’s newsroom at https://ibn.fm/ALZN.

Who is involved in the development of Alzamend’s therapies?

Alzamend is working in partnership with Massachusetts General Hospital and imaging partner QMENTA to develop its therapies.

What is the mission of Alzamend Neuro Inc.?

Alzamend Neuro Inc.’s mission is to ‘Make Alzheimer’s Just a Memory’ by advancing innovative therapies for neurological and psychiatric conditions.

How does Alzamend’s approach differ from current standards of care?

Rather than tweaking existing treatments, Alzamend is engineering bold new approaches that directly address the limitations of current standards of care, focusing on safety, efficacy, and tolerability.